Align Technology, Inc. (Nasdaq: ALGN), a leading global medical device company known for its Invisalign® clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for restorative dentistry, has announced the launch of the latest version of its Invisalign Smile Architect…
This American Pharmacists Month, XiFin Pharmacy Solutions invites pharmacy professionals to join the 2025 Pharmacy Transformation Study, which aims to identify key success factors shaping the future of pharmacy care. With growing evidence of pharmacists’ positive impact on health outcomes,…
Spok, Inc., a subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK) and a leader in healthcare communications, has published its 14th annual survey on communication practices within U.S. healthcare organizations. This survey assesses how clinical communication is managed, highlighting trends, challenges,…
Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. have announced positive topline interim results from their ongoing Phase 3 clinical trial of sibeprenlimab for treating immunoglobulin A nephropathy (IgA nephropathy) in adults. Sibeprenlimab is an investigational anti-APRIL…
CEL-SCI Corporation (NYSE American: CVM) today highlighted the promising implications for its immunotherapy Multikine® (Leukocyte Interleukin, Injection) following a recent meeting of the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC), which serves as a public forum…
AMRA Medical, in collaboration with the University of Oslo, has published a study examining the effects of antidepressants (ADs), particularly serotonin-selective reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), on muscle health and cardiometabolic risk. Conducted as part of the CoMorMent…
AptarGroup, Inc. (NYSE: ATR), a global leader in dosing, dispensing, and protection technologies for drug and consumer products, has announced the award of a contract from the U.S. Federal Government to further develop its ActivShield™ technology. This innovative solution enables…
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO® (Respiratory Syncytial Virus Vaccine), a bivalent RSV vaccine, for preventing lower respiratory tract disease (LRTD) caused by RSV in individuals aged 18 to 59…
Hello Heart, a leader in preventive heart health, has announced its expansion into government markets across the United States. This initiative aims to make its proven heart health tools accessible to millions of Americans, allowing them to manage their health…
Hesperos, Inc., a leader in human biology modeling for drug development through its Human-on-a-Chip® technology, is excited to announce the appointment of Lawrence (Larry) Florin as Chief Executive Officer. With over 20 years of leadership experience in bio and clinical…
Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on innovative treatments for neuropsychiatric disorders, announced today that its Phase 2b trial of ALTO-100 for major depressive disorder (MDD) did not achieve its primary endpoint, as measured by the…
Medpace Holdings, Inc. (Nasdaq: MEDP) has announced its financial results for the third quarter ending September 30, 2024. Third Quarter 2024 Financial Highlights Year-to-Date 2024 Financial Overview Balance Sheet and Liquidity As of September 30, 2024, Medpace had cash and…